Auris Medical Provides Business Update and Reports First Half 2019 Financial Results
15 août 2019 07h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Enrollment of first patient in TRAVERS Phase 2 trial with AM-125 in acute vertigoEnrollment completed in Phase 1b trial with AM-201 in...
Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
30 juil. 2019 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, July 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain
03 juil. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, July 03, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Holding Ltd Provides Corporate Update
23 mai 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, May 23, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule
20 mai 2019 08h45 HE
|
Auris Medical AG
Hamilton, Bermuda, May 20, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Closing of Public Offering of Common Shares
15 mai 2019 16h15 HE
|
Auris Medical AG
Hamilton, Bermuda, May 15, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD
15 mai 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, May 15, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Holding Ltd.:
13 mai 2019 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, May 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain
07 mai 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, May 07, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Reverse Stock Split
30 avr. 2019 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, April 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...